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Abstract
 
Borrelia burgdorferi
 
, the Lyme disease spirochete, persistently infects mammalian hosts despite the
development of strong humoral responses directed against the pathogen. Here we describe a
novel mechanism of immune evasion by 
 
B. burgdorferi
 
. In immunocompetent mice, spirochetes
that did not express 
 
ospC
 
 (the outer-surface protein C gene) were selected within 17 d after
inoculation, concomitantly with the emergence of anti-OspC antibody. Spirochetes with no
detectable 
 
OspC
 
 transcript that were isolated from immunocompetent mice reexpressed 
 
ospC
 
after they were either cultured in vitro or transplanted to naive immunocompetent mice, but
not in OspC-immunized mice. 
 
B. burgdorferi
 
 persistently expressed 
 
ospC
 
 in severe combined
immune-deficient (SCID) mice
 
.
 
 Passive immunization of 
 
B. burgdorferi–
 
infected SCID mice
with an anti-OspC monoclonal antibody selectively eliminated 
 
ospC
 
-expressing spirochetes but
did not clear the infection. 
 
OspC
 
-expressing spirochetes reappeared in SCID mice after the
anti-OspC antibody was eliminated. We submit that selection of surface-antigen nonexpressers
is an immune evasion mechanism that contributes to spirochetal persistence.
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Introduction
 
Lyme disease is a complex multi-system disorder with both
early and late manifestations. Early signs and symptoms in-
clude erythema migrans, acute meningitis, and Bell’s palsy,
whereas in the late phase of the disease, arthritis, chronic
neurologic abnormalities, and acrodermatitis chronica atro-
phicans are manifest (1–3). The manner whereby 
 
Borrelia
burgdorferi
 
 can chronically infect both humans (4) and ani-
mals (5–7) in the face of a vigorous and specific immune
response continues to be an enigma. Especially intriguing is
the long-term survival of the spirochete despite the pres-
ence of a strong antibody response that is directed against
surface antigens (6).
 
Several defense stratagems are potentially available to 
 
B.
burgdorferi
 
, including antigenic variation (8), seclusion into
immune privileged sites (9), and suppression of harmful
immune responses (10, 11). Like other vector-borne
pathogens, such as the protozoan 
 
Trypanosoma brucei
 
 (12)
and the spirochete 
 
Borrelia hermsii
 
 (13), 
 
B. burgdorferi
 
 ex-
presses a surface protein (VlsE) that undergoes antigenic
variation (8). While the variable surface glycoprotein of 
 
T.
brucei
 
 appears to be the only antigenic structure exposed at
the surface of this organism (12), and the variable major
protein of 
 
B. hermsii
 
 dominates the antibody response to
this relapsing fever spirochete, a large body of evidence in-
dicates that in addition to VlsE, several other surface pro-
 
teins, e.g., outer surface protein C (OspC)
 
*
 
 (14), decorin-
 
binding protein A (Dbp)A (15), the porin P66 (16), and the
fibronectin-binding protein BBK32 (17) are immunogenic,
 
and thus expressed, during a natural (tick-transmitted) 
 
B.
burgdorferi
 
 infection. Moreover, antibodies to at least some
of these surface proteins are able to partly or fully protect
mice from a challenge infection with 
 
B. burgdorferi
 
 admin-
istered either via ticks (BBK32 [17], OspC [18]) or by im-
plantation of skin biopsy tissue containing host-adapted
 
spirochetes (P66 [19]). Thus, VlsE antigenic variation cannot
 
be the only mechanism that makes it possible for 
 
B. burgdor-
feri
 
 spirochetes to establish a chronic infection. As for se-
clusion of the spirochete into classical immune privileged
sites such as the central nervous system, this indeed occurs,
yet 
 
B. burgdorferi
 
 also is readily cultivable from nonimmune-
privileged organs such as the urinary bladder, skin, and
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heart (20). It also must be available for transmission in in-
tradermal blood pools generated by blood feeding ticks
(21). Finally, 
 
B. burgdorferi
 
 lipoproteins induce in mono-
cytes the production and secretion of the anti-inflamma-
tory cytokine IL-10 (10), but IL-10 knockout mice do be-
come infected with 
 
B. burgdorferi
 
, albeit with a lower
spirochetal burden than wild-type mice (11). Thus, nei-
ther immune seclusion nor suppression are essential for
persistence of a 
 
B. burgdorferi
 
 infection.
Over the last five years it has become apparent that 
 
B.
burgdorferi
 
 is able to regulate the expression of several lipo-
proteins in response to environmental cues such as changes
in temperature, pH, or cell density. The spirochete also
differentially expresses lipoproteins in the tick and mam-
malian hosts (for a review, see reference 22). We hypothe-
sized that, as it infects the mammalian host, 
 
B. burgdorferi
 
might be able, perhaps in response to cues provided by tis-
sue microenvironments, to downregulate the expression of
surface antigens that otherwise would be targeted by bac-
tericidal antibodies gradually elicited during infection.
These antibodies would thus select surface-antigen nonex-
pressers, and these organisms, if viable, would continue to
infect the mammalian host. We tested this hypothesis by
assessing OspC mRNA expression in the skin of naive and
OspC-immunized mice as well as in SCID mice both in
the presence and absence of passively transferred anti-
OspC bactericidal antibody. Here we present the results of
these studies.
 
Materials and Methods
 
Spirochete Strain. B. burgdorferi
 
 sensu stricto clonal isolate B31
5A3, low passage (reference 8; a gift from Steven Norris, Univer-
sity of Texas, Houston, TX) was cultivated in BSK-H medium
supplemented with 10% rabbit serum (Sigma-Aldrich). Spiro-
chetes grown to either mid-logarithmic or stationary phase were
used in this study.
 
Mouse Infection and Biopsy.
 
Both C3H/HeN (C3H) and
C3H-SCID mice (6 to 8-wk-old; Charles River Laboratories and
The Jackson Laboratory, respectively) were given one single in-
tradermal injection of 10
 
4
 
 spirochetes that were grown to station-
ary phase. Mice were killed at intervals of 1–3 wk, starting at 10 d
after needle inoculation. A small piece of mouse ear was used as
source of tissue to culture spirochetes. The remaining ear tissues
were frozen immediately in liquid nitrogen for RNA preparation.
Blood samples were also collected for the analysis of antibody re-
sponses to OspC and VlsE by ELISA.
 
Mouse Immunization.
 
Three C3H mice were given two sub-
cutaneous injections at 3-wk intervals of 5 
 
 
 
g purified recombi-
nant OspC (a gift from Robert Gilmore, National Center for In-
fectious Diseases, Centers for Disease Control and Prevention,
Fort Collins, CO) emulsified with the MPL plus TDM adjuvant
(Sigma-Aldrich). As controls, an additional three mice received
two doses each of the adjuvant. 6 d after the last injection, all six
animals were inoculated with host-adapted spirochetes.
 
Mouse Inoculation with Host-adapted Spirochetes.
 
A C3H mouse
that had been infected with 
 
B. burgdorferi
 
 by needle-inoculation
was killed 2 wk postinoculation (PI). One ear was used to prepare
RNA for PCR analysis. The remaining ear was cut into small
pieces and homogenized in a 1.7-ml plastic centrifuge tube with a
 
plastic piston. The homogenate was suspended in 550 
 
 
 
l BSK-H
medium and immediately administered, subcutaneously, to the
six C3H mice that had received either rOspC plus adjuvant or
adjuvant alone The mice were killed at 14 to 18 d PI. Mouse ears
were used to prepare RNA for PCR analysis and blood samples
to assess the anti-OspC antibody titer.
 
Anti-OspC Monoclonal Antibody.
 
The hybridoma cell line was
kindly provided by Robert Gilmore (National Center for Infec-
tious Diseases, Centers for Disease Control and Prevention, Fort
Collins, CO). B5, the anti-OspC IgG2a monoclonal antibody se-
creted by this cell line was able to passively protect mice against a
tick-transmitted infection with 
 
B. burgdorferi
 
 B31 (23). B5 was
purified from mouse ascites fluid using a protein-G column
(Pierce Chemical Co.). B5 purity and concentration were as-
sessed using SDS-PAGE and the Bio-Rad protein assay kit (Bio-
Rad Laboratories), respectively.
 
Passive Immunization of SCID Mice with Anti-OspC Monoclonal
Antibody.
 
Six C3H-SCID mice were infected with 10
 
4
 
 cultured
spirochetes by subcutaneous injection. Each of two of these mice
received 2, 5, 10, 50, 100, and 100 
 
 
 
g of monoclonal antibody
B5 at 10, 12, 14, 17, 19, and 21 d PI, respectively. Another two
animals were each given three 100-
 
 
 
g doses of mAb B5 at 17,
19, and 21 d PI, while the remaining two mice were treated with
three 100-
 
 
 
g doses of purified normal mouse IgG2a (Sigma-
Aldrich) as a control. The mice were killed at 3–4 d after the last
passive immunization. Mouse ears were used to prepare RNA for
reverse transcription (RT)-PCR analysis and as a source to cul-
ture spirochetes. In a separate experiment, five C3H-SCID mice
were needle inoculated with cultured spirochetes. Four of the an-
imals received three 50-
 
 
 
g doses of antibody B5 at 10, 12, and
14 d PI and the remaining mouse was given mouse IgG2a as a
control. 3 d later, the control and one immunized mouse were
killed for RT-PCR analysis. The remaining animals were treated
with 150 and 100-
 
 
 
g doses of anti–mouse IgG antibody at 5 and
7 d, respectively, after the last passive immunization and killed ei-
ther 10 d or 2 mo later. Total RNA was purified from mouse ears
for RT-PCR analysis.
 
RNA Preparation from Cultured Spirochetes and Mouse Ear Tis-
sues.
 
Spirochetes grown to mid-logarithmic phase were har-
vested by centrifugation. Mouse ear tissues were frozen in liquid
nitrogen and homogenized. Total RNA was purified using
RNeasy Mini Kit (QIAGEN). Purified RNA preparations were
further treated with RNase-free DNase (QIAGEN) and moni-
tored for absence of residual DNA by PCR analysis using the
primers listed in Table I.
 
Probe Preparation and Southern Blotting.
 
DNA was purified
from spirochetes grown to stationary phase using DNeasy Mini
Kit (QIAGEN). Purified DNA was amplified by PCR using Taq
PCR Core Kit (QIAGEN) and the primers listed in Table I.
PCR products were purified using QIAquick PCR Purification
Kit (QIAGEN). Purified DNA fragments were digested either
with restriction endonuclease DraI or MboI (Life Technologies).
Agarose gel electrophoresis revealed the expected fragment
lengths of the digested PCR products and thus confirmed the
identity of the amplified sequences. Southern blotting was per-
formed using ECL direct nucleic acid labeling and detection sys-
tems, following the manufacturer’s instructions (Amersham Phar-
macia Biotech).
 
RT-PCR Analysis.
 
RNA samples purified from cultured spi-
rochetes or mouse ear tissues were used as templates to prepare
cDNA using Omniscript Reverse Transcriptase (QIAGEN). The
reverse primers for the genes 
 
flab
 
, 
 
ospC
 
, and 
 
vlsE
 
 are listed in Ta-
ble I. 2 
 
 
 
g of purified RNA were used in each reverse transcrip- 
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tion reaction of 20 
 
 
 
l. 5 
 
 
 
l of cDNA preparation were amplified
by PCR using Ready-TO-Go PCR beads following the manu-
facturer’s instructions (Amersham Pharmacia Biotech). RT-PCR
products were analyzed on ethidium bromide-incorporated aga-
rose gels and then transferred onto Hybond-ECL membranes for
Southern blotting.
 
ELISA.
 
OspC ELISA was performed as described previously
(24). Recombinant OspC antigen was cloned from 
 
B. burgdorferi
 
B31 (a gift from Robert Gilmore). The sequence of peptide Ct
and the peptide-based ELISA were described elsewhere (25, 26).
The Ct sequence reproduced that of the COOH-terminal invari-
able domain of VlsE of 
 
B. burgdorferi
 
 B31 (8). Mouse sera were se-
rially diluted two- to fourfold and reacted with recombinant
OspC or peptide Ct bound to an ELISA plate. Titer was defined
as the highest serum dilution at which the ELISA OD (optical
density) was 
 
 
 
 the mean OD value of the preimmune sera of all
of the mice plus 3 standard deviations.
 
Results
 
Spirochetes Not Expressing OspC Are Selected Concomitantly
with the Appearance of Anti-OspC Antibody.
 
We first in-
fected a group of five mice of the C3H/HeN (C3H) strain
by needle inoculation and killed them individually at 10,
17, 24, 45, and 66 d PI. We purified total ear RNA and
subjected it to RT-PCR to amplify the transcripts of the
 
ospC, flaB
 
, and 
 
vlsE
 
 genes (Table I). As expected, both the
 
flaB
 
 and 
 
vlsE
 
 gene transcripts were persistently expressed
during the whole study (Fig. 1). In contrast, and in agree-
ment with our hypothesis, the 
 
ospC
 
 gene transcript was de-
tected only at day 10 PI but not thereafter (Fig. 1). These
results indicated that the infection continued despite the di-
 
minished or ceased expression of OspC. We confirmed the
identity of all of the RT-PCR amplicons by Southern blot
with gene-specific probes (data not shown). A separate set
of five mice was infected and processed in the same fashion
and essentially identical results were obtained (not shown).
As the 
 
ospC
 
 gene is located on a plasmid (cp26) (27), se-
lection of cp26-negative spirochetes might explain the neg-
ative RT-PCR results. However, spirochetes isolated from
the ear of mice that had shown no detectable 
 
ospC
 
 gene
expression did express the 
 
ospC
 
 transcript after cultivation
in vitro (Fig. 1). This result indicated that in the course of
infection, spirochetes had been selected whose 
 
ospC
 
 gene
was shut down but not lost.
If spirochetes expressing OspC are effectively selected
against by the gradual appearance of anti-OspC antibody
during the course of infection, the titer of anti-OspC anti-
body should increase early in this process and perhaps
eventually decline, as OspC ceases to be expressed. This
turned out to be the case. The anti-OspC IgG antibody ti-
ter was 1:1,600 as early as day 10 PI. A peak titer value of
1:6,400 was reached by day 24, and after remaining at that
level by day 45 PI, it declined to 1:3,200 at day 66 PI. We
also titrated anti-OspC IgG antibody in the second set of
five mice and similar results were obtained. For compari-
son, we titrated anti-VlsE antibody using as antigen a pep-
tide (Ct) whose amino acid sequence reproduces that of the
COOH-terminal invariable domain of VlsE (8, 25, 26).
Unlike antibodies to the variable regions of VlsE,
which may be bactericidal (8), antibodies recognizing the
COOH-terminal invariable domain of VlsE are not, for al-
though this domain is immunodominant, it is not exposed
 
Table I.
 
PCR Primers
 
Gene Forward Reverse
 
flaB
 
5
 
 
 
-CTGGCAAGATTAATGCTCAA-3
 
 
 
5
 
 
 
-CAGGAGAATTAACTCCACCT-3
 
 
 
ospC
 
5
 
 
 
-CATTAAGTGCAATATTAATGAC-3
 
 
 
5
 
 
 
-AAGCATCTCTTTAGCTGCT-3
 
 
 
vlsE
 
5
 
 
 
-AGTACGACGGGGAAACCAG-3
 
 
 
5
 
 
 
-TTTGCGAACTGCAGACTCAGCA-3
 
 
Figure 1. Selection of OspC nonexpressers as infec-
tion progresses. Five C3H mice were infected with
cultured spirochetes and killed at 10 (mouse QI11), 17
(QI12), 24 (QI13), 45 (QI15), and 66 d (QI16) PI.
Total RNA was purified from cultured spirochetes
(cultured Bb), mouse ear tissues, or reisolated spiro-
chetes (reisolated Bb), and analyzed by RT-PCR for
expression of the flaB,  ospC, and vlsE genes. PCR
products were separated by ethidium bromide-incor-
porated-agarose gel electrophoresis. 
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on the surface of 
 
B. burgdorferi (
 
25, 26). Unlike with anti-
OspC antibody, the anti-VlsE (Ct) antibody titer increased
continually up to the last time point measured, with a value
of 1:1,600 at day 10 PI and of 1:638,400 at 66 d PI. This
result is consistent with the continuous expression of VlsE
during this period (Fig. 1).
 
Anti-OspC Antibody Is Both Necessary and Sufficient to Se-
lect Spirochetes that Do Not Express OspC during Infection.
 
As an initial assessment of the role of antibody in selecting
 
ospC
 
 nonexpressers, we immunized three C3H mice with
purified recombinant OspC and adjuvant. 10 d after the last
immunization, a time at which anti-OspC antibody was
detectable in the serum of the immunized mice, we in-
fected these animals and another group of three mice that
had received adjuvant alone, with host-adapted spirochetes.
This was achieved by implanting ear tissue from a donor
C3H mouse that had been infected with 
 
B. burgdorferi
 
 for 2
wk. RT-PCR of ear RNA from this mouse showed that
the resident spirochetes did not express 
 
ospC
 
 but continued
to express the 
 
flaB
 
 and 
 
vlsE
 
 gene transcripts (not shown).
We killed the six mice between 14 and 18 d PI. RT-PCR
revealed that spirochetes reexpressed 
 
ospC
 
 in each of the
three naive mice but in none of the immunized animals
(Fig. 2).
In a separate experiment, we infected five naive C3H
mice with host-adapted spirochetes that had downregulated
 
ospC
 
. This gene was reexpressed in all of the five recipients,
as evidenced by the appearance of anti-OspC antibody (de-
 
termined by OspC-ELISA, data not shown). After 24 d of
infection 
 
OspC
 
 expression was no longer detectable, as re-
vealed by RT-PCR (data not shown). This time period
was longer than the 17 d recorded in mice that were in-
fected with cultured spirochetes (Fig. 1). The longer 
 
ospC
 
expression period was probably due to a more slowly de-
veloping anti-OspC antibody response in mice infected
with host-adapted spirochetes (initially not expressing
OspC). We then infected four C3H SCID mice by needle
inoculation with cultured spirochetes and killed them indi-
vidually at 10, 17, 31, and 47 d PI. When we analyzed pu-
rified ear RNA by RT-PCR it became apparent that, as
with the 
 
flab
 
 and 
 
vlsE
 
 gene transcripts in normal mice, the
 
ospC
 
 transcript, as well as the 
 
flaB
 
 and 
 
vlsE
 
 transcripts, were
continually expressed throughout the 47-d study period
(Fig. 3). These results indicated that anti-OspC antibody
was necessary to positively select spirochetes not expressing
 
ospC
 
. They indicated, moreover, that OspC
 
 
 
 spirochetes
were the more viable phenotype, as they appeared to be
positively reselected in the absence, or at lower levels, of
anti-OspC antibody.
To ascertain if antibody was also sufficient to modulate
the balance between the OspC- and OspC
 
 
 
 phenotypes,
we needle inoculated six SCID mice with cultured spiro-
chetes. Four of them received either six (mice QI51 and
QI52) or three doses of a protective anti-OspC mono-
clonal antibody (23) (mice QI53 and QI54). The remain-
ing two animals (QI55 and QI56) received three doses of
purified mouse IgG2a (the same isotype as the monoclonal
antibody) as control. 
 
OspC
 
 mRNA was detectable only in
the ear biopsy tissue of mice that had received normal
IgG2a. No 
 
ospC
 
 transcript was detected in the mice treated
with the anti-OspC monoclonal antibody, regardless of
whether the animals had received three or six doses of the
antibody (Fig. 4). These results confirmed that anti-OspC
Figure 2. OspC nonexpressers reverted to expressing ospC in the absence
of anti-OspC antibody but not when antibody was present. Mice QM25,
QM26, and QM27 received two doses of recombinant OspC emulsified
with adjuvant while QM22, QM23, and QM24 were given adjuvant
alone. 10 d after the last immunization, all of the mice were inoculated
with host-adapted spirochetes that had downregulated ospC. Mice QM22
and QM25 were killed at 14 d postchallenge and the rest at 18 d postchal-
lenge. Total RNA was purified from ear tissues and analyzed by RT-PCR
for expression of the genes flaB, ospC, and vlsE. PCR products were sepa-
rated by ethidium bromide–incorporated agarose gel electrophoresis.
Figure 3. B. burgdorferi persistently expressed ospC in SCID mice. Four
C3H-SCID mice were infected with cultured spirochetes and killed at 10
(mouse QH94), 17 (QH95), 31 (QH96), and 47 d (QH97) PI. Total
RNA was purified from mouse ear tissues and analyzed by RT-PCR for
expression of the genes flaB, ospC, and vlsE. PCR products were sepa-
rated by ethidium bromide–incorporated agarose gel electrophoresis. 
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antibody was sufficient to effect selection of non-OspC–
expressing spirochetes.
To further substantiate this tenet, we examined if 
 
B.
burgdorferi
 
 reexpressed 
 
ospC
 
 after the anti-OspC antibody
had disappeared. We first passively immunized four
infected SCID mice with the anti-OspC monoclonal
antibody. After the 
 
ospC
 
 gene was downregulated, we
neutralized the antibody by treatment of the mice with
anti–mouse IgG. Although 
 
ospC
 
 expression remained un-
detectable at 10 d after the clearance of specific antibody, 2
mo after this time spirochetes reexpressed the 
 
ospC
 
 tran-
script (Fig. 5).
 
Discussion
 
The evidence we have put forward strongly supports the
notion that anti-OspC antibody is either able to select
OspC-negative phenotypes that coexist with OspC-
expressing spirochetes or can induce the downregulation of
 
OspC expression in a manner that is reversible and depen-
dent on antibody titer. While we are not aware that such
an inductive mechanism exists, it constitutes a hypothesis
that is readily testable in vitro. As for the hypothesis of se-
lection of OspC-negative spirochetes, which we find the
more plausible of the two, others have shown that OspC-
negative spirochetes are present in the infectious inoculum
derived from a tick. Ohnishi et al. analyzed OspC expres-
sion in the spirochetes present in the skin attached to the
mouthparts of a feeding tick and found both OspC
 
 
 
 and
OspC
 
 
 
 organisms (28). Thus OspC
 
 
 
 organisms might be
present and available for selection as of the very onset of in-
fection. In our experiments, by day 17 post-needle inocu-
lation, no OspC transcripts were detectable by RT-PCR
in the ears of infected mice.
Although we verified the identity of all of the transcripts
we analyzed by Southern blot, we did not attempt to assess
by this technique mRNA expression at a level not detect-
able by ethidium bromide staining. Therefore, our results
Figure 4. Passively trans-
ferred anti-OspC antibody se-
lectively eliminated OspC-
expressing spirochetes in
infected SCID mice. Six SCID
mice were infected with cul-
tured spirochetes. Mice QI51
and QI52 were passively immu-
nized with 2, 5, 10, 50, 100,
and 100  g anti-OspC mono-
clonal antibody at 10, 12, 14,
17, 19, and 21 d PI and were
killed 3 d later. Mice QI53 and
QI54 were passively immunized
with three doses of 100  g anti-
OspC monoclonal antibody
whereas mice QI55 and QI56
were given three doses of 100
 g mouse IgG2a isotype control
at 17, 19, and 21 d PI and were
killed 4 d later. Total RNA was purified from mouse ear tissues and analyzed by RT-PCR for expression of the genes flaB, ospC, and vlsE. PCR
products were separated by ethidium bromide–incorporated agarose gel electrophoresis.
Figure 5. B. burgdorferi reex-
pressed ospC in passively immu-
nized SCID mice after specific
antibody was cleared. Five SCID
mice were inoculated with cul-
tured spirochetes. Mice QM54,
QM55, QM56, and QM57 were
passively immunized with three
doses of anti-OspC monoclonal
antibody at 10, 12, and 14 d PI
while mouse QM53 was given
IgG2a isotype control. Mice
QM53 and QM54 were killed
3 d later. QM55, QM56, and
QM57 received two doses of
anti–mouse IgG at 5 and 7 d af-
ter the last passive immunization. Mouse QM55 was killed at 10 d after receiving the secondary antibody while QM56 and QM57 were killed at 2 mo.
Total RNA was purified from mouse ear tissues and analyzed by RT-PCR for expression of the genes flaB, ospC, and vlsE. PCR products were separated
by ethidium bromide–incorporated agarose gel. 
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only allow us to state that 
 
ospC
 
 expression is diminished
below our detection levels. While this is of course always
so, regardless of the sensitivity of the detection technique
used, it is a matter of importance in this case, for we can-
not state that OspC
 
 
 
 spirochetes were completely elimi-
nated. Hence, the reappearance of detectable OspC
 
 
 
 or-
ganisms both in vitro (Fig. 1) and in vivo (Fig. 2 and 5) in
the absence of antibody does not automatically entail that
OspC
 
 
 
 spirochetes can revert to the OspC
 
 
 
 phenotype. A
small surviving population of OspC
 
 
 
 spirochetes may be
favorably reselected in the absence of anti-OspC antibody.
Furthermore, we do not know if spirochetes do in fact
switch between OspC
 
 
 
 and OspC
 
 
 
 phenotypes within the
mammalian host.
A 
 
B. burgdorferi
 
 surface protein whose expression has
been described as controlled by the same regulatory net-
work as that of OspC is decorin-binding protein A (DbpA)
(29). The alternative sigma factors RpoS and RpoN are
both involved in this network (29). When spirochetes are
cultivated in vitro in an environment that mimics that of
the midgut of an engorging tick, i.e., 37
 
 
 
C, pH 6.8, and in-
creased spirochetal cell density, the expression of both
OspC and DbpA is upregulated (30). In vivo the pattern of
expression of these two proteins differs somewhat in that,
while OspC expression is upregulated in the feeding tick,
expression of DbpA is not detected in this environment but
only shortly after infection of the mammalian host (15). In-
terestingly, when mice immunized with DbpA are infected
via tick-bite, the anti-DbpA antibody does not protect the
host against infection, yet when naive mice are thus in-
fected, anti-DbpA antibody is elicited in the course of in-
fection (15). Thus, on the one hand, DbpA is expressed by
 
B. burgdorferi
 
 in the tick-infected mammalian host but on
the other, anti-DbpA antibody is not protective regardless
of whether it is induced by infection or vaccination. This
paradox may be explained by assuming that, as with OspC,
DbpA-expressing spirochetes are eventually selected against
within the mammalian host.
That the adaptive immune response is involved in the
selection (or induction) process leading to the predomi-
nance of the OspC
 
 
 
 phenotype was clearly demonstrated
by the persistence of OspC
 
 
 
 organisms in SCID mice (Fig.
3). The sufficiency of antibody to effect the selection of
OspC
 
 
 
 spirochetes was demonstrated by the reconstitution
of this process in SCID mice that had been given anti-
OspC antibody (Figs. 4 and 5). As we analyzed the anti-
body response to OspC in C3H mice, we noticed that, in
contrast to the titer of anti-VlsE (Ct) antibody, which in-
creased continually, the anti-OspC antibody titer peaked
early and then began to decrease, following closely the pat-
tern of expression of the OspC transcript. In SCID mice,
the disappearance of passively transferred anti-OspC anti-
body eventually resulted in the reappearance of spirochetes
expressing 
 
ospC
 
 (Fig. 5). We would therefore predict that if
in immunocompetent mice the anti-OspC antibody titer
were to decline sufficiently, the o
 
spC
 
 transcript might be-
come detectable again, as spirochetes of the OspC
 
 
 
 pheno-
type again predominate. This should lead to a renewed in-
crease in anti-OspC antibody. In fact, when Fung and
coworkers (31) serially studied the humoral immune re-
sponse to OspC in humans, they noticed that the anti-
OspC antibody level oscillated over time, perhaps reflect-
ing the phenomenon we observed in mice. The anti-VlsE
antibody response pattern we observed in mice, albeit for
only 66 d, also echoes our observations made both in dogs
and in monkeys. In these animals, anti-VlsE antibody, as
measured by the response to the invariable region (IR)6 of
VlsE, remained essentially unchanged for years (24, 32).
And in humans, the anti-IR6 response was detected with
very high sensitivity in patients with late Lyme disease (24).
Recently, Zhong and colleagues communicated that
while active immunization of disease-susceptible AKR/N
mice with OspC led to prevention but not resolution of
disease and infection (33), passive transfer of OspC immune
serum resulted in a dose-dependent resolution of fully es-
tablished arthritis and carditis as well as infection in needle-
challenged C.B-17 SCID mice (33, 34). On the face of it
the latter result contradicts our findings. However, experi-
mental protocol differences such as, among many others,
type and dose of anti-OspC antibody, spirochetal and
mouse strains, and infectious dose precludes a meaningful
interpretation of result differences.
OspC is an antigenically diverse molecule (35, 36). In
fact, the 
 
ospC variation of B. burgdorferi sensu stricto alone
within a local population (Shelter Island, NY), as assessed
by single-strand conformation polymorphism, was shown
to be almost as great as the variation of a similarly sized
sample of the entire species (35). However, this diversity
appears to be entirely unrelated to the ability of B. burgdor-
feri to establish a chronic infection. Barthold and coworkers
have assessed whether OspC diversity could be arrived at
by immune selective pressure imposed by anti-OspC anti-
body during infection in mice (37, 38). In a most recent se-
ries of experiments, mice were infected with clonal B. burg-
dorferi sensu stricto N40 or B. afzelii PKo and then were
hyperimmunized with homologous recombinant OspC.
After 6 mo, a comparison of gene sequences among 4 B.
burgdorferi sensu stricto N40 and 9 B. afzelii PKo isolates
from OspC-immunized mice revealed no ospC variation
from input inocula. The authors concluded that variation
in  ospC among B. burgdorferi isolates and species during
chronic infection is not likely to be an important mecha-
nism of immune evasion (38).
Sequencing of the B. burgdorferi genome has uncovered
no less that 161 paralogous gene families (39, 40). At least
one of these families of genes, ospE/ospF (a.k.a. erp, p21,
pG, elpA, elpB, bbk2.10, and bbk2.11) encodes molecules
likely to be exposed on the spirochete surface (41, 42).
Mutation and recombination of ospE-related genes result in
the development of new antigenic variants and it has been
suggested that this process contributes to immune evasion
during a B. burgdorferi infection (43). This is a plausible
mechanism that may contribute, together with VlsE anti-
genic variation to the establishment of chronic infection.
The mechanism we propose, selection of nonexpressers,
should apply preeminently to surface antigens that are not421 Liang et al.
part of a polymorphic gene family and are not themselves
the subject of an antigenic variation mechanism, e.g.,
OspC, DbpA, BBK32, and P66.
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